- Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy-associated with an HIV-protease inhibitor. N Engl J Med 1998; 339: 1296.
- Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–8.
- Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ, Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389–98.
- Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine cohort, France, 1999. Groupe d’Epidemiologie Clinique du Syndrome d’Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31: 1482–7.
- Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31: 50–5.
- Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4: 293–301.
- Tretli S, Lund-Larsen PG, Foss OP Reliability of questionnaire information on cardiovascular disease and diabetes: cardiovascular disease study in Finnmark county. J Epidemiol Community Health 1982; 36: 269–73.
- Cooper DA, Carr A, Mauss S, Mulligan K. Reaching a consensus:lipodystrophy case definition. Antiviral Therapy 1999; 4: 75 /7.
- Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726–35.
- Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 1811–22.
- Sattler F. Body changes related to lipodystrophy. Clin Infect Dis 2003; 36: S84–90.
- Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971–9.
- Rajab A, Heathcote K, Joshi S, Jeffery S, Patton M. Heterogeneity for congenital generalized lipodystrophy in 17 patients from Oman. Am J Med Genet 2002; 110: 219–25.
- Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musicco M, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13: 465–71.
- Schinina V, Busi RE, Zaccarelli M, Carvelli C, Bibbolino C. Gynaecomastia in male HIV patients: MRI and US findings. Clin Imaging 2002; 26: 309–13.
- Piroth L, Grappin M, Petit JM, Buisson M, Duong M, Chavanet P, et al. Incidence of gynaecomastia in men infected with HIV and treated with highly active antiretroviral therapy. Scand J Infect Dis 2001; 33: 559–60.
- Calista D, Boschini A. Cutaneous side effects induced by indinavir. Eur J Dermatol 2000; 10: 292–6.
- Colson AE, Keller MJ, Sax PE, Pettus PT, Platt R, Choo PW Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 27–32.
- Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322: 1098–105.
- Brinkman K, Smeitink JA, Romijn JA, Reiss P Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112–5.
Scandinavian Journal of Infectious Diseases
Volume 36, 2004 - Issue 3